




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 239/94, 403/12, 409/12 C07D 495/04, 405/12, 491/04 C07D 487/04, A61K 31/505	A1	(11) International Publication Number: WO 93/08170 (43) International Publication Date: 29 April 1993 (29.04.93)
(21) International Application Number: PCT/US92/08991 (22) International Filing Date: 23 October 1992 (23.10.92) (30) Priority data: 07/782,850 24 October 1991 (24.10.91) US (71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; 685 Third Avenue, New York, NY 10017 (US). (72) Inventors: PRIMEAU, John, Laurent ; 20 Sunset Avenue, Princeton, NJ 08540 (US). GARRICK, Lloyd, Michael ; 1814 Polo Run Drive, Yardley, PA 19067 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corporation, 685 Third Avenue, New York, NY 10017 (US) et al.		(81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II ANTAGONISTS <div style="text-align: center;">  </div> (57) Abstract <p>There are disclosed compounds of general formula (I), wherein A is O, S, NR⁶, -CR⁷=CR⁸; Z is O, S, NR⁶, -CR⁷=CR⁸; X is H, NR⁹R¹⁰, OR¹¹, CN, F, Cl, I, Br, perfluoroalkyl, alkyl, alkyl-OH, alkoxyalkyl, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰; with the proviso that when Z = -CR⁷=CR⁸ then Y is NR¹³, NR¹³CR¹²R¹⁴, CR¹²R¹⁴NR¹³; with the proviso that when Z = O, S, NR⁶ then Y is NR¹³CR¹²R¹⁴; R¹ is 5-tetrazolyl, CO₂R¹¹, SO₃H, NHSO₂CH₃, NHSO₂CF₃; R², R³, R⁴, R⁷, R⁸ is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰, OR¹¹, F, Cl, Br, I, NR⁹R¹⁰; with the proviso that when A = -CR⁷=CR⁸ then R⁵ is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰, -OH, OR¹¹, F, Cl, Br, I, NR⁹R¹⁰; with the proviso that when A = O, S, NR⁶ then R⁵ is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰; R⁶ is H, alkyl, aralkyl; R⁹, R¹⁰ is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl; R¹¹ is H, alkyl, aralkyl, alkoxyalkyl; R¹², R¹⁴ is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰; R¹³ is H, OR¹¹, alkyl, perfluoroalkyl, aralkyl, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰; n is 0, 1, 2 or 3; wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine and the pharmaceutically acceptable salts, solvates and hydrates thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart failure. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

**SUBSTITUTED HETEROCYCLES AS ANGIOTENSIN II
ANTAGONISTS**

BACKGROUND OF INVENTION

5

The compounds described in this invention as well as their non-toxic salts and pharmaceutical compositions containing them are useful for the treatment of hypertension and congestive heart failure. These compounds are also useful as lipid
10 lowering agents.

The renin-angiotensin system plays a well-defined role in cardiovascular homeostasis [Ocin, T.D. et al. (1991) *Drugs of the Future* 16, 37-51]. Angiotensinogen is converted to angiotensin I by the enzyme renin. Angiotensin I is
15 then acted upon by angiotensin converting enzyme (ACE) to form Angiotensin II (A II). A II possesses many crucial properties including vasoconstriction, aldosterone release, and water retention and is implicated as the cause of high blood pressure in a number of species including man. These hypertensive responses are the result of A II acting at specific receptor sites. Compounds which are able to compete with A II for
20 these receptor sites but do not elicit agonistic receptor responses can be expected to counteract (antagonize) the hypertensive effects of A II.

PRIOR ART

25 E. E. Allen et al describe 4-oxo-quinazolines in *EP 0411766 A*.

D. A. Roberts et al describe quinoline ethers in *EP 0412848 A*.

D. J. Carini et al in *U.S. patent 4,880,804* describe N-substituted
30 benzimidazoles. P. Chakravarty et al disclose similar imidazole structures in *EP 0401030 A* where the phenyl aromatic ring is replaced by a seven membered heterocycle.

E. E. Allen et al disclose N-substituted oxypyrimidines in *EP 0419048 A*.

35


Similar structures are reported in *EP 0424317 A* by P. Herold et al.

- 2 -

Our invention differs from the above mentioned prior art in that we disclose non-peptidic amino substituted nitrogenous 6 membered heterocycles fused to 5 or 6 membered aromatic rings. The non-peptidic A II antagonists disclosed in the above mentioned prior art are either oxo-quinazolines, quinoline ethers, benzimidazoles, fused heterocyclic imidazoles or oxo-pyrimidines.

DESCRIPTION OF INVENTION

This invention describes the composition and utility of novel heterocycles of the general formula I:



I

wherein

A is O, S, NR⁶, -CR⁷=CR⁸;

Z is O, S, NR⁶, -CR⁷=CR⁸;

X is H, NR⁹R¹⁰, OR¹¹, CN, F, Cl, I, Br, perfluoroalkyl, alkyl,

alkyl-OH, alkoxyalkyl, -(CH₂)_nCO₂R¹¹,

-(CH₂)_nCONR⁹R¹⁰;

with the proviso that when Z = -CR⁷=CR⁸ then Y is NR¹³, NR¹³CR¹²R¹⁴, CR¹²R¹⁴NR¹³;

with the proviso that when Z = O, S, NR⁶ then Y is NR¹³CR¹²R¹⁴;

R¹ is 5-tetrazolyl, CO₂R¹¹, SO₃H, NHSO₂CH₃, NHSO₂CF₃;

R², R³, R⁴, R⁷, R⁸ is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³,

-(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰, OR¹¹, F, Cl, Br, I, NR⁹R¹⁰;

- 3 -

- with the proviso that when $A = -CR^7=CR^8$ - then R^5 is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, NO_2 , SO_2R^{13} , $-(CH_2)_nCO_2R^{11}$, $-(CH_2)_nCONR^9R^{10}$, -OH, OR^{11} , F, Cl, Br, I, NR^9R^{10} ;
- 5 with the proviso that when $A = O, S, NR^6$ then R^5 is alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, NO_2 , SO_2R^{13} , $-(CH_2)_nCO_2R^{11}$, $-(CH_2)_nCONR^9R^{10}$;
- 10 R^6 is H, alkyl, aralkyl;
- R^9, R^{10} is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl;
- R^{11} is H, alkyl, aralkyl, alkoxyalkyl;
- R^{12}, R^{14} is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO_2 , SO_2R^{13} ,
- 15 $(CH_2)_nCO_2R^{11}$, $-(CH_2)_nCONR^9R^{10}$;
- R^{13} is H, OR^{11} , alkyl, perfluoroalkyl, aralkyl, $-(CH_2)_nCO_2R^{11}$, $-(CH_2)_nCONR^9R^{10}$;
- n is 0, 1, 2 or 3;
- 20 wherein alkyl is defined as 1-8 carbons, branched or straightchain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine, and N-oxides thereof and the pharmaceutically acceptable salts of the compounds of formula (I) and the N-oxides..
- 25 A preferred aspect of the present invention are the compounds represented by the general formula I wherein:
- A is S, $-CR^7=CR^8$;
- Z is S, $-CR^7=CR^8$;
- 30 X is H, CN, F, Cl, perfluoroalkyl, alkyl, alkyl-OH, alkoxyalkyl, $-(CH_2)_nCO_2R^{11}$, $(CH_2)_nCONR^9R^{10}$;
- with the proviso that when $Z = -CR^7=CR^8$ - then Y is $-NR^{13}$, $-NR^{13}CR^{12}R^{14}$;
- 35 with the proviso that when $Z = S$, then Y is $NR^{13}CR^{12}R^{14}$;
- R^1 is 5-tetrazolyl, CO_2H , SO_3H , $NHSO_2CF_3$;

- 4 -

$R^2, R^3, R^4, R^7, R^8 = H, \text{ alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO}_2, \text{SO}_2R^{13},$
 $-(CH_2)_nCO_2R^{11}, -(CH_2)_nCONR^9R^{10}, OR^{11}, F, Cl, Br, I,$
 $NR^9R^{10};$

5 with the proviso that when $A = -CR^7=CR^8-$ then R^5 is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, $NO_2, SO_2R^{13}, -(CH_2)_nCO_2R^{11},$
 $-(CH_2)_nCONR^9R^{10}, -OH, OR^{11}, F, Cl, Br, I, NR^9R^{10};$

10 with the proviso that when $A = S$ then R^5 is alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, $NO_2, SO_2R^{13}, -(CH_2)_nCO_2R^{11}, -(CH_2)_nCONR^9R^{10};$

R^9, R^{10} is H, alkyl, perfluoroalkyl, aralkyl;

R^{11} is H, alkyl, aralkyl, alkoxyalkyl;

R^{12}, R^{14} is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH,

15 perfluoroalkyl, aralkyl, CN, $NO_2;$

R^{13} is H, OR^{11} , alkyl, perfluoroalkyl, aralkyl,

$-(CH_2)_nCO_2R^{11}, -(CH_2)_nCONR^9R^{10};$

n is 0, 1, 2 or 3;

20 wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine and the pharmaceutically acceptable salts thereof.

25 A more preferred aspect of the present invention are the compounds represented by the general formula I wherein:

A is $-CR^7=CR^8-$, S;

Z is $-CR^7=CR^8-$, S

X is H, Cl, perfluoroalkyl, alkyl;

30 with the proviso that when $Z = -CR^7=CR^8-$ then Y is $-NR^{13},$
 $-NR^{13}CR^{12}R^{14};$

with the proviso that when $Z = S$, then Y is $NR^{13}CR^{12}R^{14};$

R^1 is 5-tetrazolyl, $CO_2H, SO_3H, NHSO_2CF_3;$

R^2, R^3, R^4, R^7, R^8 is H, alkyl, alkoxyalkyl, alkyl-OH,

35 perfluoroalkyl, aralkyl, CN, $NO_2, SO_2R^{13}, OR^{11}, F, Cl,$
 Br, I, $NR^9R^{10};$

- 5 -

with the proviso that when $A = -CR^7=CR^8-$ then R^5 is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, NO_2 , SO_2R^{13} , -OH, OR^{11} , F, Cl, Br, I, NR^9R^{10} ;

with the proviso that when $A = S$ then R^5 is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN, NO_2 , SO_2R^{13} ;

R^9, R^{10} is H, alkyl, perfluoroalkyl, aralkyl;

R^{11} is H, alkyl, aralkyl, alkoxyalkyl;

R^{12}, R^{14} is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl;


R^{13} is H, OR^{11} , alkyl, perfluoroalkyl, aralkyl;

n is 0, 1, 2 or 3;

wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine and the pharmaceutically acceptable salts thereof.

The following are specific examples of the invention.

20 Series I



- 6 -


Example	R ¹³	R ¹	R ⁸	R ⁷	R ⁵	R ⁴	X
4	H	-CO ₂ Me	H	H	H	H	Cl
10	H	-CO ₂ H	H	OMe	OMe	H	Cl
26	H	-CO ₂ Me	H	OMe	OMe	H	HNnBu
22	H	-CO ₂ Me	H	H	H	H	-HNipentyl
23	H	-CO ₂ H	H	H	H	H	-HNipentyl
5	H	-CO ₂ Na	H	H	H	H	Cl
27	H	-CO ₂ H	H	H	H	H	NH(CH ₂) ₂ - OMe
28	H	-CO ₂ H	H	OMe	OMe	H	-HNnBu
29	H	-CO ₂ Me	H	OMe	OMe	H	-OH
24	H	CO ₂ Me	H	OMe	OMe	H	OMe
19	H	CO ₂ Me	H	H	H	H	OH
2	H	CO ₂ Me	H	Cl	H	H	Cl
3	H	CO ₂ Na	H	Cl	H	H	Cl
20	H	CO ₂ H	H	H	H	H	OH
11	H	CO ₂ H	H	H	H	H	H
30	H	CO ₂ H	H	H	H	H	-HNnBu
21	H	CO ₂ Me	H	H	H	H	OAc
7	H	CO ₂ Me	H	H	H	H	CF ₃
8	H	CO ₂ Na	H	H	H	H	CF ₃
6	H	5- tetrazolyl	H	H	H	H	CF ₃
9	H	5- tetrazolyl	H	H	H	H	Cl
1	H	CO ₂ Na	H	H	Cl	H	CF ₃
12	H	CO ₂ Na	H	H	H	H	CF ₂ CF ₃
13	H	CO ₂ Me	H	H	H	H	CF ₂ CF ₃
31	-CH ₂ - CO ₂ Me	-CO ₂ - CH ₂ CO ₂ - Me	H	H	H	H	CF ₃
14	H	CO ₂ H	H	H	CF ₃	H	CF ₃
32	-CH ₂ - CO ₂ H	CO ₂ H	H	H	H	H	CF ₃

- 7 -

15	H	5-	H	CH ₃	H	H	CF ₃
		tetrazolyl					
16	H	5-	H	H	H	CH ₃	CF ₃
		tetrazolyl					
17	H	5-	CH ₃	H	H	H	CF ₃
		tetrazolyl					
18a	H	CO ₂ Na	H	H	H	H	CH ₃
25	CH ₃	CO ₂ Na	H	H	H	H	CF ₃
18b	H	5-	H	H	H	H	CH ₃
		tetrazolyl					


SERIES II

5



Example	R ¹³	R ¹	R ⁵	R ⁴	-	-	X
33	H	CO ₂ Me	H	H	-	-	Cl
34	H	CO ₂ Na	H	H	-	-	Cl
35	H	5-tetrazolyl	H	H	-	-	CF ₃
36	H	CO ₂ Na	H	H	-	-	CF ₃
37	H	5-tetrazolyl	H	H	-	-	Cl

- 8 -

SERIES III

5


Example

41

R^{13}	R^1	R^8	R^4	R^5	R^7	X
H	CO ₂ Na	H	H	H	H	CF ₃

SERIES IV

10

Example

40

39


38

R^{13}	R^1	R^8	R^4	R^5	R^7	X
H	CO ₂ Na	H	H	H	H	CF ₃
H	CO ₂ Na	H	H	H	H	CF ₂ CF ₃
H	CO ₂ Me	H	H	H	H	CF ₂ CF ₃

15


PROCESS OF INVENTION**Process Disclosure**

- 5 The compounds of the invention may be prepared by a process which comprises
 (a) condensing, eg in the presence of a base, a compound of formula



with a compound of formula

10



wherein the above formulae R, R², R³, R⁴, R⁵, X and Z are as defined above and

- 15 (i) Z¹ is a leaving group, such as halogen (eg. chlorine), a methanesulphonyloxy group or a p-toluenesulphonyloxy group, and Y¹ is NHR¹³ or NHR¹³CR¹²R¹⁴ (where R¹², R¹³ and R¹⁴ are as defined above)

or

20


- (ii) Z¹ is -NHR¹³ or -CR¹²R¹⁴NHR¹³ and Y¹ is a leaving group (where R¹², R¹³ and R¹⁴ are as defined above)

or

25


- (b) reacting a compound of formula

- 10 -



where R^4 , R^5 , A, X, Y and Z are as defined above and Z^2 is chloro or bromo with an aryl species of formula

5




$Q = B(OH)_2$ or MgX^1 or ZnX^1 (where X^1 is halogen, preferably chlorine or bromine)

in the presence or absence of a catalytic compound containing palladium or nickel
where R^1 and R^2 are as defined above

10

or

(c) converting an oxazoline of formula



15

(where R^3 , R^4 , R^5 , A, X, Y and Z are as defined above) into a compound of formula I
in which R^2 is hydrogen and R^1 is 5-tetrazolyl or $-CO_2R^{11}$ (where R^{11} is defined
above) by methods known per se (for example, by the procedures described in US-A-

20

or

(d) converting one compound of formula (I) into another compound of formula (I) by methods known per se, for example:

- 5 (i) reacting a compound of formula (I) in which X is halo (eg. chloro) with a nucleophile (eg. an amine, an alcohol such as methanol or water), for example under acid or base catalysis to give a compound of formula I in which X is NR⁹, R¹⁰ or OR¹¹

or

10

- (ii) hydrolysing an ester to give an acid

or

- 15 (e) forming a salt of the compound of formula (I) with an inorganic or organic base

or


- 20 (f) converting a compound of formula (I) or a salt thereof to an N-oxide by means of a peroxidising agent, eg. hydrogen peroxide.

The above process and the preparation of representative starting material for these processes are described below with reference to various schemes. These schemes illustrate methods which are generally applicable to the preparation of other compounds of the invention. Starting materials not specifically exemplified are known in the art or may be prepared by analogous methods from known starting materials.


30 The compounds of general formula **1** can be prepared as described in *scheme 1*.
bThe 4-chloroquinazoline **2** can be reacted with the aminomethylbiphenyl **3** in the presence of a base such as sodium acetate or potassium carbonate in tetrahydrofuran or tetrahydrofuran/dioxane at room temperature to reflux. The 2-haloquinazoline **4** (X=Cl) can be converted to **1** by the addition of a nucleophile such as an amine, methanol or water under acid or base catalysis.

35

- 12 -

SCHEME 1

Alternately compounds **4** can be prepared as shown in *scheme 2*. The bromophenylquinazolines **5** can be prepared by reacting the 4-chloroquinazoline with p-bromobenzylamine, followed by protection of the benzylic nitrogen with a suitable protecting group as described by T. W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1981. Conversion of **5** to its Grignard reagent, followed by the reaction of this with the oxazoline shown using the procedure of A. L. Meyers, et. al., *J. Am. Chem. Soc.*, **97**, 7383, 1975, yields **6**. Conversion of the oxazoline **6** to its corresponding acid, ester and tetrazole can be carried out using the procedures described by Carini et. al. *U. S. patent 4,880,804*.


SCHEME 2

wherein R^4 , R^5 and X are as defined above and R is a protecting group


15

The preparation of compounds **3** shown in *scheme 1* has been disclosed by Carini et. al. *U. S. patent 4,880,804*, *EP 0324377*, *EP 0323841*, *EP 0253310*.

The 4-chloroquinazoline **2a** (where $X=H$) can be synthesized as shown in *scheme 3*. This preparation was described by W. B. Lutz et. al. *U. S. patent 3,266,990*.

SCHEME 3

The 4-chloroquinazolines **2b** and **2c** (where X=Cl and CF₃) can be prepared as described in *scheme 4*. Reaction of the substituted anthranilic acid **7** with urea in refluxing pyridine yields the quinazolinediones **2**. Reaction of the analogous anthranilamide **8** with trifluoroacetamide yields the 2-trifluoromethylquinazolones **10a**. Reaction of **2** or **10a** with POCl₃ in the presence of dimethylaniline (DMA) using the procedure reported by T. H. Althius and H. J. Hess (for **2** to **2b** where R¹=6-OMe and R²=7-OMe); *J. Med. Chem.*, 1977, 20, 146 , yields the 4-chloroquinazolines **2b** or **2c** respectively. Alternately this transformation can be carried out by the procedure described by N. A. Lange et al (for **2** to **2b** where R¹=R²=H); *J. Amer. Chem. Soc.*, 1930, 52, 3696.


SCHEME 4

15


The preparation of 2-methyl-4-chloroquinazoline **2d** has been described by E. S. Hand et al; *Can. J. Chem.* 1984, 62, 2570. This procedure can also be used to convert the 2-ethyl-4-quinazolone **10b** reported by N. A. Dolgova et al; *Izv. Akad. Nauk. Kaz. SSSR Ser. Khim.*, 1989, #2, 26, to the 4-chloroquinazoline **2e**.

20

- 14 -




2d. R=Me
2e. R=Et

**10b**


The thienopyrimidine compounds **12** are prepared as shown in *scheme 5* using the same reaction conditions as those described in *scheme 1*.

5

SCHEME 5**11****12**

wherein R^1 , R^4 and X are as defined above

- The preparation of the starting 4-chlorothiopyrimidine **11** is described in *scheme 6*.
- 10 Reaction of 3-amino-2-carboxamidethiophene with urea led to the thienopyrimidinedione **14**. Similar reaction with trifluoroacetamide led to the 2-trifluoromethylpyrimidone **15**. These materials were converted to **11a** and **11b** using $POCl_3$, catalysed with dimethylaniline (DMA).



SCHEME 6

15



- 15 -

Substitution of pentafluoropropanamide for trifluoroacetamide in *schemes 4 and 6* leads to the formation of compounds **16** and **17**. Using these starting materials in *schemes 1 and 5* provides compounds **18** and **19**.

5







wherein R^4, R^5 are as defined above



wherein R^1, R^4, R^5 are as defined above

10

Replacement of the aminomethylbiphenyl compounds **3** in *schemes 1 and 5* with compounds **20** and **21** leads to the formation of the substituted quinazolines **22** and **23**, and the substituted thienopyrimidines **24** and **25**.




wherein R^1, R^4, R^5 and X are as defined above

15

The preparation of this amino ester **20** is described in *scheme 7*.

SCHEME 7




5

Treatment of the methoxyphenyloxazoline **26** with 2-lithiothiophene leads to the substituted thiophene **27**. Methylation using n-BuLi and methyl iodide followed by acid hydrolysis leads to the 2-substituted benzoic acid. Esterification and bromination

leads to **29** which is treated under Gabriel conditions to generate the desired amine **20**. The amino ester **30** is prepared as illustrated in *scheme 8*. The commercially available 2-biphenylcarboxylic acid **31** is nitrated using concentrated nitric acid in acetic acid (1:1.9) to yield the previously reported nitro-acid **32** previously reported by S. A. Glover et al, *J. Chem. Soc. Perkin I*, 1981, 842. Esterification followed by reduction over palladium yields the desired amino ester **30**.

15

SCHEME 8



20

The compounds of this invention may also form salts with inorganic or organic bases. Any pharmaceutically acceptable salts of these compounds are within the scope of this invention. These salts may be, but are not limited to, ammonium salts, alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium, dicyclohexylamine salts, TRIS salts, and salts of amino acids. These compounds may also be converted to N-oxides by treatment with hydrogen peroxide by conventional means.

The present invention also provides a pharmaceutical composition which comprises a compound of this invention and a pharmaceutically acceptable carrier. In particular, the present invention provides an anti-hypertensive pharmaceutical composition which comprises an antihypertensive effective amount of a compound of this invention and a pharmaceutically acceptable carrier.

The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration for patients suffering from heart failure.

In order to obtain consistency of administration, it is preferred that a composition of the invention is in the form of a unit dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 1 to 50 mg. The compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg. Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day. The compounds may also be administered in a parenteral dosing form.

The compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that used for known antihypertensive agents, diuretics, b-blocking agents or ACE inhibitors.

The present invention further provides a compound of the invention for use as an active therapeutic substance. Compounds described in this invention are of particular use in the treatment of hypertension. They can also be used for the treatment of congestive heart-failure. In addition, the compounds of this invention also have therapeutic utility in the treatment of hyperlipidemia, and/or hypercholesterolemia.

The present invention further provides a method of treating hypertension in mammals including man, which comprises administering to the afflicted mammal an antihypertensive effective amount of a compound or a pharmaceutical composition of the invention.

The high affinity of the compounds for the angiotensin II receptor was established using a rat adrenal receptor binding assay, measuring the displacement of radiolabeled angiotensin II from the receptor, described as follows: Anesthetize male Sprague-Dawley rats (300-400 g body weight) with CO₂ and sacrifice by cervical dislocation. Dissect adrenal glands and keep in ice-cold sucrose buffer. (0.2 M sucrose, 1 mM EDTA, 10 mM Trizma base, pH = 7.2). Remove medulla by squashing. Mince

the cortex, rinse and homogenize in a chilled ground glass tissue grinder with 15 mL sucrose buffer. Centrifuge at 3000 x g for 10 min. (Sorvall RCSC centrifuge, SS34 rotor 6200 rpm). Decant supernatant through gauze. Centrifuge combined supernatants at 12000 x g for 13 min. (Beckman ultracentrifuge, 80Ti rotor, 13000 rpm). Centrifuge the supernatant from the previous step at 102000 x g for 60 min. (Beckman ultracentrifuge, 80Ti rotor, 38200 rpm). All steps are carried out at 4°C. Resuspend the pellet in 0.5 mL assay buffer (50 mM Tris HCl, 5 mM MgCl₂, 0.2% BSA (protease-free), pH = 7.4, 25°C). Store on ice. Determine membrane protein by Lowry or Bradford assay with BSA as standard. The binding assay is performed in triplicate, in 12x75 mm plastic test tubes or in 96-well plate (final volume of 0.25 mL). Add 140 mL assay buffer. Add 10 mL cold A II (to give final concentrations of 10⁻¹⁰-10⁻⁷ M for standard curve and 10⁻⁴ M for nonspecific binding), compounds (e.g., for final concentrations of 25 and 100 mM or 1 mM, 10 nM and 100 nM) in 50% DMSO, or 50% DMSO as a control. Add 50 mL membrane suspension (e.g., 10 mg protein). Preincubate for 30 min at 25°C. Add 50 ml ¹²⁵I-A II which has been prepared as shown below (final concentration= 1 nM). Incubate for 35 min at 25°C. Stop the incubation by adding 1 mL ice-cold buffer (assay buffer without BSA). Filter with GF/C filters on cell harvester (filters are presoaked in the assay buffer containing 1% polyethyleneimine). Rinse assay tubes 3X with 5 mL cold buffer (assay buffer without BSA). Cut and deposit the filter discs into test tubes and count on gamma counter for 1 min. Adjust the specific activity of ¹²⁵I-A II purchased from New England Nuclear to 500 mCi/nmole by adding cold A II in water. Calculate the quantities of hot A II and the cold A II needed and make the dilution. Aliquot, seal tight, and store frozen until needed. Calculate the concentration of the total A II (hot + cold) after dilution. On the day of assay, thaw the frozen aliquot and adjust the volume to give a concentration of 5 pmole/mL (or 0.25 pmole/50 mL) with assay buffer (+ protease-free BSA). For final concentration of 1 nM ¹²⁵I-A II in the assay, add 50 mL (or 0.25 pmole) per test tube to a final volume of 250 mL. The results of these binding assays are reported as the inhibitory concentration of the test compound necessary to achieve fifty percent displacement of radiolabeled angiotensin II from its receptor (IC₅₀), or the percent displacement of binding of A II at its receptor at 10⁻⁸M concentration of test compound (% I). All the examples cited in this invention displayed significant inhibition of A II binding in this assay. Typically these compounds displayed an IC₅₀ in this assay of less than or equal to 150µM.

In accordance with their ability to antagonize angiotensin II, the compounds of this invention show antihypertensive action in the following A II-infused rat model.

Rats are anesthetized with Dial-Urethane (0.60 mL/kg, ip) and the trachea cannulated with PE 240. Either one femoral artery and both femoral veins or the carotid artery and the corresponding jugular vein are cannulated with PE 50. If the jugular vein is cannulated, two cannulas are placed in the one vein. The initial portion of the duodenum (just distal to the stomach) is cannulated with PE 50 *via* a small midline incision. Arterial pressure and heart rate are measured from the arterial cannula. Ten to 15 min are allowed following surgery for stabilization of arterial pressure. Ganglion blockade is then produced by intravenous administration of mecamylamine at 3 mg/kg (1 mL/kg of a 3 mg/mL solution). Ganglion blockade causes a fall in arterial pressure of about 50 mmHg. Mecamylamine is given every 90 min throughout the remainder of the experiment. An A II infusion is then begun into the other venous cannula at 0.25 mg/kg/min (at 9.6 μ L/min). The A II infusion returns arterial pressure to or slightly above the control level. Once arterial pressure has stabilized with the A II infusion, baseline values for mean arterial pressure (MAP) and heart rate are taken. The test compound, suspended in methyl cellulose, is then administered *via* the duodenal cannula at 0.1, 3 or, 30 mg/kg in a volume of 1 mL/kg. Mean arterial pressure and heart rate values are tabulated at 15, 30, 60, 90, 120, 150, 180, 210, and 240 min after administration of the test compound. For example, the product of Example 36 administered at 10 mg/kg id lowered the A II dependent blood pressure by an average of 45% one half hour post-administration.

As illustrated above the compounds of this invention are effective A II antagonists and therefore are useful for treating hypertension. They are also of value in the management of acute and chronic congestive heart failure, primary and secondary pulmonary hyperaldosteronism, secondary hyperaldosteronism, primary and secondary pulmonary hypertension, hypertension associated with oral contraceptive use, vascular disorders such as migraine, Raynaud's disease, luminal hyperplasia and the atherosclerotic process, renal diseases or renal complications of other diseases or therapies such as proteinuria, glomerulonephritis, glomerular sclerosis, scleroderma, diabetic nephropathy, end stage renal disease, renal transplant therapy and others. These compounds will also be useful in the treatment of left ventricular dysfunction, diabetic retinopathy, Alzheimers disease, in the enhancement of cognition, in treatment of elevated intraocular pressure, and in the enhancement of retinal blood flow. These compounds will also be useful as antidepressants and anxiolytics and in the prevention or treatment of restenosis following angioplasty. The application of the compounds of this invention for these and similar disorders will be apparent to those skilled in the art.

- 20 -

The usefulness of these compounds as lipid lowering agents was assessed using cholesterol absorption in a cholesterol/cholic acid-fed rat model which is described as follows. Newly arrived rats are housed for 5 days in a room with reversed light/dark cycle and fed pelleted rat chow (Purina 5001). The food is removed, and the rats are placed on a daily 4 h/day feeding schedule (beginning at 9:00 AM) with normal chow for 7 days. After acclimation (total of 12 days) and randomization based on weight, dosing with drugs and feeding of cholesterol/cholic acid is initiated. Drug solubilized in vehicle (0.1 mL; olive oil, corn oil, 2% Tween 80, or carboxymethyl cellulose) is administered orally through a dosing needle immediately prior to (9:00 AM) and immediately following the 4 h feeding period. Dosing with drugs and feeding of the cholesterol/cholic acid diet is repeated for 4 days. On the morning of the 5th day, rats are sacrificed (decapitation), blood is collected and the livers are removed, weighed and stored frozen (-80°C). The animals are analyzed for total plasma cholesterol (TPC), high density lipoprotein cholesterol (HDL, Sigma kit) and triglycerides (TG) on an Abbott Autoanalyzer. VLDL + LDL cholesterol is calculated by the difference between total and HDL cholesterol. HDL cholesterol/total cholesterol is also calculated. Typically the compounds of this invention show a 50% drop in total cholesterol at doses in the range of 100-200 mg/kg.

As illustrated above the compounds of this invention are effective lipid lowering agents and therefore are useful for treating hyperlipidemia and/or hypercholesterolemia.

Specific procedures are described in the following experimental examples. These examples are given to illustrate the invention and should not be construed as limiting the invention set forth in the appended claims.

25

EXPERIMENTAL

Example 1

The preparation of 4'-[[[7-chloro-2-trifluoromethyl-4-quinazolinyl)amino]methyl]-[1,1'-biphenyl]-2-carboxylic acid.

Part A

30

The preparation of 4-chloro-2-nitrobenzamide.

To 25 mL of a 2M solution of thionyl chloride in methylene chloride was added 5.0 g of 4-chloro-2-nitrobenzoic acid. The reaction mixture was refluxed for approximately 18 hours. The reaction mixture was cooled to room temperature and was added dropwise to excess 28% aqueous ammonia held at -30°C. Additional

- 21 -

CH₂Cl₂ (50 mL) was added and the organic layer was recovered, dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was taken up in ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to yield the product as a tan powder (4.92 g, 99%): ¹H NMR (DMSO-d₆, 300MHz) δ 8.25 (bs, 1H), 8.14 (m, 1H), 7.87 (m, 1H), 7.78 (bs, 1H), 7.68(m, 1H).

Part B

The preparation of 4-chloro-2-aminobenzamide.

10

To 70 mL of glacial acetic acid was added 4-chloro-2-nitrobenzamide (2.0 g) and iron powder (2.8 g). The reaction mixture was heated at 90°C for 2 hours. The reaction mixture was cooled to room temperature and all solvents were removed by evaporation. The residue was taken up in a mixture of ethyl acetate and saturated aqueous sodium carbonate. This mixture was filtered through celite and the organic phase was recovered and washed with brine. The organic phase was then dried over anhydrous magnesium sulfate, filtered and evaporated to yield 1.65 g of the product as a buff powder (97%): ¹H NMR (DMSO-d₆, 300MHz) δ 7.75 (bs, 1H), 7.55 (d, 1H), 7.15 (bs, 1H), 6.82 (bs, 2H), 6.73 (d, 1H), 6.45 (dd, 1H).

20

Part C

The preparation of 7-chloro-2-trifluoromethyl-4-quinazalone.

Trifluoroacetamide (1.64 g) and 4-chloro-2-aminobenzamide (1.65 g) were mixed intimately and were heated under nitrogen to 180°C for 4 hours. The reaction solution was cooled to room temperature and solidified. The resulting solid was recrystallized from absolute ethanol to yield 0.51 g (21%) of the product as a buff powder: ¹H NMR (DMSO-d₆, 300MHz) δ 13.78 (bs, 1H), 8.20 (m, 1H), 7.92 (d, 1H), 7.75 (m, 1H).

30

Part D

The preparation of 4,7-dichloro-2-trifluoromethylquinazoline.

35

To a mixture of POCl₃ (5 mL) and dimethyl aniline (0.5 mL) was added 0.51 g of 7-chloro-2-trifluoromethyl-4-quinazalone. The reaction was refluxed for 3 1/2

- 22 -

hours, cooled to room temperature and quenched into an ice cold mixture of diethyl ether and water. The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated to yield a yellow brown solid (0.52 g, 94%): ^1H NMR (DMSO- d_6 , 300MHz) δ 8.43 (m, 2H), 8.10 (m, 1H).

5

Part E

The preparation of 4'-[[[(7-chloro-2-trifluoromethyl-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid.

10

To 25 mL of tetrahydrofuran were added sodium acetate (0.5 g), 4,7-dichloro-2-trifluoromethyl quinazoline (0.33 g) and 4' aminomethyl (1,1'-biphenyl)-2-carboxylic acid. The reaction mixture was stirred at 40°-50°C for approximately 18 hours. All the THF was removed by evaporation and the residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The resulting residue was purified by silica chromatography to yield 0.54 g (98%) of the title product as an off-white powder. The compound was characterized as the sodium salt: ^1H NMR (DMSO- d_6 , 300MHz) δ 10.20 (s, 1H), 8.52 (d, J=9Hz, 1H), 7.87 (d, J=2Hz, 1H), 7.63 (dd, J=2.2,8.8Hz, 1H), 7.38 (m, 5H), 7.22 (m, 3H), 4.74 (d, J=5.6Hz); negative FAB MS m/e 456(M-Na). Anal. calcd for $\text{C}_{23}\text{H}_{14}\text{F}_3\text{ClINaO}_2 \cdot 1.5\text{H}_2\text{O}$: C, 54.50; H, 3.38; N, 8.29. Found: C, 54.35; H, 3.45; N, 8.46.

15

20

Example 2

25

The preparation of 4'-[[[(2,6-dichloro-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

Part A

30

Preparation of 5-chloro-2-aminobenzamide.

35

To 5-chloro-2-nitrobenzamide (2.0 g) (prepared according to the procedure described in Example 1, Part A) was added 50 mL of glacial acetic acid. This solution was heated to 90°C and iron powder (2.8 g) was added in small portions over 15 minutes. When addition was complete the reaction mixture was stirred at 90°-100°C. After 2 hours the reaction was cooled to room temperature and was evaporated to

- 23 -

dryness. The resulting residue was partitioned between ethyl acetate and aqueous sodium carbonate. This brown slurry was filtered and the ethyl acetate layer was recovered and washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to dryness to yield 1.7 g (100%) of a buff powder: ¹H NMR (DMSO-d₆, 300MHz) δ 7.83 (bs, 1H), 7.59 (d, 1H), 7.17 (bs, 1H), 7.14 (dd, 1H), 6.70 (m, 3H).

Part B

The preparation of 6-chloro-2,4-quinazoline-dione.

10

Urea (2.64 g) and 5-chloro-2-amino benzamide (3.75 g) were dissolved in 100 mL of pyridine. To this solution was added 10% HCl (aq.) (6 drops) and the resulting solution was refluxed for 12-18 hours. The reaction mixture was evaporated to dryness and the resulting residue was suspended in 125 mL of water. The pH of the suspension was adjusted to 6 with dilute hydrochloric acid and the solid was recovered by filtration. The filter cake was washed well with water and was dried to yield 3.27 g of buff powder (76%): ¹H NMR (DMSO-d₆, 300MHz) δ 11.45 (s, 1H), 11.25 (s, 1H), 7.81 (d, 1H), 7.66 (dd, 1H), 7.18 (d, 1H).

20

Part C

The preparation of 2,4,6-trichloroquinazoline.

A mixture of 6-chloro-2,4-quinazolidinedione (3.27 g) in 30 mL of phosphorous oxychloride and 1.5 mL of dimethylaniline was refluxed for 4 1/2 hours. The reaction was cooled to room temperature and was poured into a 0°C mixture of 300 mL of diethyl ether and 300 mL of water. The ether layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to dryness to yield 3.54 g of a brown/yellow solid (91%): ¹H NMR (DMSO-d₆, 300MHz) δ 8.325 (m, 1H), 8.20 (m, 1H), 8.085 (m, 1H).

30

Part D

The preparation of 4'-[(2,6-dichloro-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

35

- 24 -

A mixture of sodium acetate (0.44 g), 2,4,6-trichloroquinazoline, (0.42 g) and 4'-amino methyl(1,1'-biphenyl)-2-carboxylic acid methyl ester, hydrochloride (0.47 g) in 10 mL of THF was stirred at room temperature for 5 days. At that time all solvents were removed by evaporation and the residue was partitioned between ethyl acetate and
5 brine. The ethyl acetate fraction was dried over anhydrous magnesium sulfate, filtered and evaporated. The crude material was purified using silica gel chromatography to yield 0.45 g (58%) of the product as a yellow powder (m.p.=98°-102°C); ¹H NMR (DMSO-d₆, 400MHz) δ 9.40 (t, J=5.9Hz, 1H), 8.50 (d, J=2.2Hz, 1H), 7.83 (dd, J=2.3, 8.9Hz, 1H), 7.71 (dd, J=1.1, 7.7Hz, 1H), 7.66 (d, J=8.9Hz, 1H), 7.59 (dt, J=1.4, 7.6Hz, 1H), 7.46 (m, 1H), 7.40 (m, 3H), 7.26 (m, 2H), 4.79 (d, J=5.7Hz, 2H), 3.58(s, 3H); EI MS m/e 437(M⁺). Anal. calcd for C₂₃H₁₇Cl₂N₃O₂: C, 63.03; H, 3.91; N, 9.59. Found: C, 63.13; H, 3.95; N, 9.31.

Example 3

15

The preparation of 4'-[[[(2,6-dichloro-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid.

A mixture of sodium acetate (0.56 g), 2,4,6-trichloroquinazoline (0.40 g) and
20 4'-aminomethyl (1,1'-biphenyl)-2-carboxylic acid (0.43 g) was stirred at room temperature in 10 mL of THF for 5 days. All solvents were removed by evaporation and the resulting residue was partitioned between ethyl acetate and brine. The ethyl acetate fraction was dried over anhydrous magnesium sulfate, filtered and evaporated. The crude material was purified using silica gel chromatography to yield 0.15 g (21%)
25 of an off white solid (m.p.= 210°-240°C): ¹H NMR (DMSO-d₆, 400MHz) δ 9.45 (t, J=6.2Hz, 1H), 8.52 (d, J=2.3Hz, 1H), 7.83 (dd, J=2.3, 8.9Hz, 1H), 7.66 (m, 2H), 7.49 (m, 1H), 7.35 (m, 7H), 4.77 (d, J=5.2Hz); negative FAB MS m/e 422(M-H). Anal. calcd for C₂₂H₁₅Cl₂N₃O₂: C, 62.28; H, 3.56; N, 9.90. Found: C, 62.44; H, 3.52; N, 9.95.

30

Example 4

The preparation of 4'-[[[(2-chloro-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

35

Sodium acetate (0.65 g), 2,4-dichloroquinazoline (0.52 g) and 4'-aminomethyl-[1,1'-biphenyl]-2-carboxylic acid methyl ester (0.73 g) were suspended in 25 mL of

- 25 -

tetrahydrofuran. The reaction was stirred at room temperature for approximately 18 hours at which time the solvents were evaporated. The residue was loaded onto a silica gel column and the desired product was eluted with ethyl acetate/hexane (1:1). The yield was 0.75 g (71%) (m.p.=75°-90°C): ¹H NMR (DMSO-d₆, 300MHz) δ 9.30 (t, J=6Hz, 1H), 8.33 (d, J=8.1Hz, 1H), 7.81 (m, 1H), 7.71 (m, 1H), 7.60 (m, 3H), 7.45 (m, 4H), 7.25 (d, J=8.1Hz, 2H), 4.80 (d, J=5.8Hz, 2H), 3.58 (s, 3H); positive FAB MS m/e 404(MH). Anal. calcd for C₂₃H₁₈ClN₃O₂: C, 68.40; H, 4.49; N, 10.40. Found: C, 68.09; H, 4.57; N, 10.10.

10

Example 5

The preparation of 4'-[[[(2-chloro-4-quinazolinyl)amino]methyl][1,1'-diphenyl]-2-carboxylic acid.

15

Procedure 1

To a solution of 0.245 g of 4'-[[[(2-chloro-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid, methyl ester in 10 mL of 1:1 MeOH:Dioxane was added. 3.6 mL of 0.5 N aqueous sodium hydroxide. The reaction solution was stirred at room temperature for 10 days. All solvents were removed by evaporation and the residue was neutralized with hydrochloric acid. The resulting solid was filtered off and washed well with water. This was purified using silica gel chromatography to yield 0.074 g of the desired product (m.p.=223°-233°C): ¹H NMR (DMSO-d₆, 400MHz) δ 12.70 (bs, 1H), 9.38 (t, J=6.1Hz, 1H), 8.34 (d, J=7.5Hz, 1H), 7.83-7.22 (m, 11H), 4.80 (d, J=5.8Hz, 2H); negative FAB MS m/e 388(M-H). Anal. calcd for C₂₂H₁₆ClN₃O₂: C, 67.78; H, 4.14; N, 10.78. Found: C, 67.91; H, 4.34; N, 10.68.

25

Procedure 2

30

To 50 mL of THF were added 0.46 g of 2,4-dichloroquinazoline, 0.58 g of 4-(aminomethyl)(1,1'-biphenyl)-2-carboxylic acid and 0.76 g of sodium acetate. The reaction mixture was stirred at room temperature for 2 days. At that time all solvents were evaporated and the resulting residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated to yield 0.44 g (49%) of the desired product. This product was identical to that obtained from procedure 1 described above.

35

- 26 -

Example 6

The preparation of N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-trifluoromethyl-4-quinazolinamine.

5

Part A

The preparation of 2-trifluoromethyl-4-quinazolone.

10

To 12 g of trifluoroacetamide was added 3.34 g of 2-aminobenzamide. The mixture was mixed intimately and was heated to 160°C for 5 hours. The reaction mixture was cooled and the resulting solid was recrystallized from ethanol to yield 3.7 g (70.3%) of the desired product: ¹H NMR (DMSO-d₆, 300MHz) δ 13.80 (bs, 1H), 8.21 (dd, 1H), 7.95 (m, 1H), 7.82 (m, 1H), 7.65 (m, 1H).

15

Part B

The preparation of 4-chloro-2-trifluoromethyl quinazoline.

20

To 20 mL of phosphorous oxychloride was added 3.02 g of 2-trifluoromethyl-4-quinazolone and 2 mL of dimethylaniline. The resulting mixture was heated at reflux for 4 1/2 hours and then cooled to room temperature. The reaction was quenched into a 0°C mixture of diethyl ether and water. The organic layer was recovered, washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to yield 3.30 g of the desired product as a yellow/brown solid: ¹H NMR (DMSO-d₆, 300MHz) δ 8.43 (m, 1H), 8.29 (m, 2H), 8.08 (m, 1H).

25

Part C

30

The preparation of N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-trifluoromethyl-4-quinazolinamine.

35

Sodium acetate (1.27 g), 4-chloro-2-trifluoromethylquinazoline (0.72 g) and N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amine (0.78 g) were added to 25 mL of THF. The resulting suspension was stirred at 40°-50°C for 72 hours. All the THF was evaporated and the resulting residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and

- 27 -

evaporated. The residue was purified on silica chromatography to yield 0.97 g (70%) of the desired product. The compound was characterized as the potassium salt: ^1H NMR (DMSO- d_6 , 400 MHz) δ 9.39 (t, $J=5.9$ Hz, 1H), 8.39 (d, $J=8.5$ Hz, 1H), 7.85 (m, 2H), 7.66 (m, 1H), 7.51 (m, 1H), 7.33 (m, 3H), 7.22 (d, 8.1 Hz, 2H), 7.07 (d, 8.2 Hz, 2H); negative FAB MS m/e 484 (M - H); 446 (M - K). Anal Calcd for $\text{C}_{23}\text{H}_{15}\text{F}_3\text{KN}_3\cdot\text{H}_2\text{O}$: C, 54.86; H, 3.40; N, 19.47. Found: C, 54.61; H, 3.30; N, 19.38.

Example 7

10 The preparation of 4'-[[[2-trifluoromethyl-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

Sodium acetate (2.34 g), 4'-aminomethyl(1,1'-biphenyl)-2-carboxylic acid, methyl ester (1.99 g) and 1.66 g of 4-chloro-2-trifluoromethylquinazoline were added to 50 mL of tetrahydrofuran. The resulting suspension was stirred at 40°-50°C for 72 hours. All the THF was removed by evaporation and the residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel chromatography to yield. 3.46 g (40%) of the desired product (M.P.=135°-142°C): ^1H NMR (DMSO- d_6 , 400 MHz) δ 9.43 (t, $J=6$ Hz, 1H), 8.41 (d, 7.9 Hz, 1H), 7.88 (m, 2H), 7.70 (m, 2H), 7.58 (m, 1H), 7.43 (m, 4H), 7.25 (m, 2H), 4.85 (d, $J=5.9$ Hz, 2H), 3.56 (s, 3H); positive FAB MS m/e 438 (MH). Anal Calcd for $\text{C}_{24}\text{H}_{18}\text{F}_3\text{N}_3\text{O}_2\cdot 0.5\text{H}_2\text{O}$: C, 64.57; H, 4.29; N, 9.41. Found: C, 64.83; H, 4.02; N, 9.48.

25

Example 8

The preparation of 4'-[[[2-trifluoromethyl-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid.

30 In 20 mL of dioxane/methanol (1:1) was dissolved 0.245 g of 4'-[[[2-trifluoromethyl-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester. Aqueous sodium hydroxide (10 mL, 0.1 N) was added and the solution was warmed to ~40°C for 18-24 hours. All solvents were evaporated and the residue was neutralized with hydrochloric acid (2N) and extracted into ethyl acetate. The ethyl acetate layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel chromatography to yield 0.210 g (88%) of the product. The product was characterized as the sodium salt: ^1H NMR (DMSO- d_6 , 300

- 28 -

mHz) δ 9.71 (m, 1H), 8.45 (d, $J=8.1$ Hz, 1H), 7.86 (m, 2H), 7.64 (m, 1H), 7.39 (m, 5H), 7.21 (m, 3H), 4.80 (d, $J=5.8$ Hz, 2H); positive FAB MS m/e 446 (MNa), 424 (MH). Anal Calcd for $C_{23}H_{15}F_3N_3NaO_2 \cdot 1.5 H_2O$: C, 58.48; H, 3.84; N, 8.90. Found: C, 58.70; H, 3.53; N, 9.18.


5

Example 9

The preparation of 2-chloro-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-quinazolinamine.

- 10 To 50 mL of tetrahydrofuran were added 2,4-dichloroquinazoline (0.30 g). N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl amine hydrochloride (0.434 g) and 2.0 g of sodium acetate. The resulting suspension was stirred at room temperature for 53 hours at which time all the THF was removed by evaporation. The residue was purified by silica gel chromatography to yield 0.234 g of the desired product. (38%).
- 15 The product was characterized as its sodium salt: 1H NMR (DMSO- d_6 , 400 MHz) δ 9.30 (t, $J=5.9$ Hz, 1H), 8.31 (d, $J=7.8$ Hz, 1H), 7.79 (m, 1H), 7.61 (d, $J=8.4$ Hz, 1H), 7.52 (m, 2H), 7.32 (m, 3H), 7.18 (d, $J=8.2$ Hz, 2H), 7.07 (d, $J=8.2$ Hz, 2H), 4.72 (d, $J=5.8$ Hz, 2H); negative FAB MS m/e 412 (M-Na)

- 20 The following examples were or can be prepared using the procedures described in Examples 1-9.



Example	R ¹³	R ¹	R ⁸	R ⁷	R ⁵	R ⁴	X
10	H	-CO ₂ H	H	OMe	OMe	H	Cl
11	H	CO ₂ H	H	H	H	H	H
12	H	CO ₂ Na	H	H	H	H	CF ₂ CF ₃
13	H	CO ₂ Me	H	H	H	H	CF ₂ CF ₃
14	H	CO ₂ H	H	H	CF ₃	H	CF ₃
15	H	5-tetrazolyl	H	CH ₃	H	H	CF ₃
16	H	5-tetrazolyl	H	H	H	CH ₃	CF ₃
17	H	5-tetrazolyl	CH ₃	H	H	H	CF ₃
18a	H	CO ₂ Na	H	H	H	H	CH ₃
18b	H	5-tetrazolyl	H	H	H	H	CH ₃

Example 19

- 5 The preparation of 4'-[[[(1,2-dihydro-2-oxo-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

To 30 mL of dioxane were added 0.94 g of 4'-[[2,-chloro-4-quinazolinyl)-amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester, 0.53 g of wet
 10 isopentanol and 0.5 mL of hydrogen chloride in dioxane (4N). The resulting solution was refluxed for 8 days at which time all solvents were removed. The residue was partitioned between ethyl acetate and saturated aqueous sodium carbonate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel chromatography to yield 0.37 g
 15 (41%) of the desired product (M.P.=140°-160°C): ¹H NMR (DMSO-d₆, 400 MHz) δ 10.70 (s, 1H), 8.86 (t, J=6.0 Hz, 1H), 8.09 (d, J=8.0 Hz, 1H), 7.70 (dd, J=1.3, 7.6 Hz, 1H), 7.59 (m, 2H); 7.44 (m, 4H), 7.24 (m, 2H); 7.12 (m, 2H), 4.75 (d, J=5.8 Hz, 2H), 3.59 (s, 3H); CI MS m/e 386 (M+H). Anal. Calcd for C₂₃H₁₉N₃O₃•0.25H₂O: C, 70.89; H, 5.04; N, 10.78. Found: C, 70.84; H, 4.71;
 20 N, 10.62.

Example 20

The preparation of 4'-[[[(1,2-dihydro-2-oxo-4-quinazolinyl)amino]methyl][1,1'-biphenyl]-2-carboxylic acid.

5 To a solution of 0.26 g of 4'-[[[(1,2-dihydro-2-oxo-4-quinazolinyl)amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester in 5.0 mL of methanol was added 15 mL of 0.1N aqueous sodium hydroxide. The solution was warmed to ~90°C for 3 days. After cooling to room temperature the solution was neutralized with 0.1 N
10 HCl and the resulting precipitate was filtered off and washed with water. After drying, the solid was purified on silica gel chromatography to yield 0.160 g (64%) of the desired product. The product was characterized as its sodium salt: ¹H NMR (DMSO-d₆, 400 MHz) δ 10.69 (s, 1H), 9.00 (t, J=5.8 Hz, 1H), 8.11 (d, J=8.0 Hz, 1H), 7.52 (m, 1H), 7.41 (d, J=8.2 Hz, 2H), 7.28 (m, 3H), 7.14 (m, 5H), 4.68 (d, J=5.6 Hz,
15 2H); negative FAB MS m/e 392 (M-H); 370 (M-Na). Anal. Calcd for C₂₂H₁₆N₃NaO₃•1H₂O: C, 64.23; H, 4.41; N, 10.21. Found: C, 64.43; H, 4.19; N, 9.82.

Example 21

20 The preparation of 4'-[[[2-(acetyloxy)-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methylester.

To a solution of 0.183 g of 4'-[[[(1,2-dihydro-2-oxo-4-quinazolinyl)amino]-
25 methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester in 50 mL of THF and 0.067 g of N-methylmorpholine was added 0.045 g of acetyl chloride. The reaction was stirred for 1 hour and all solvents were evaporated. The residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel to yield 0.08 g of the
30 desired product (40%) and 0.11 g of the starting material (m.p.=69°-78°C): ¹H NMR (DMSO-d₆, 400 MHz) δ 9.35 (bs, 1H), 8.22 (m, 1H), 7.70 (m, 2H), 7.60 (m, 1H), 7.30-7.50 (m, 6H), 7.26 (m, 2H), 4.80 (bs, 2H), 3.60 (s, 3H), 2.59 (s, 3H); positive FAB MS m/e 428 (MH); 450 (MNa). Anal. Calcd for C₂₅H₂₁N₃O₄•0.5H₂O: C, 68.79; H, 5.08; N, 9.63. Found: C, 68.75; H, 5.01; N, 9.48.

Example 22

The preparation of 4'-[[[2-[(3-methylbutyl)amino]-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

5

To a solution of 0.310 g of 4'-[[2-chloro-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester in 24 mL of dioxane was added followed by 0.34 g of isopentyl amine hydrochloride. The solution was refluxed for 3 days at which time all the dioxane was evaporated. The resulting residue was taken up in ethyl acetate and washed with saturated aqueous sodium carbonate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel chromatography to yield 0.250 g (71%) of the desired product (m.p.=52°-58°C decomp.): ¹H NMR (DMSO-d₆, 400 MHz) δ 8.42 (bs, 1H), 8.01 (m, 1H), 7.70 (m, 1H), 7.59 (m, 1H), 7.46 (m, 2H), 7.39 (m, 3H), 7.23 (m, 3H), 7.02 (m, 1H), 6.46 (bs, 1H, 1H), 4.78 (d, J=5.8 Hz, 2H), 3.58 (s, 3H), 3.27 (m, 2H), 1.6 (m, 1H), 1.40 (m, 2H), 0.86 (d, J=6.0 Hz, 6H); positive FAB MS m/e 455 (MH). Anal. Calcd for C₂₈H₃₀N₄O₂•1/2 H₂O: C, 72.54; H, 6.74; N, 12.09. Found: C, 72.51; H, 6.66; N, 11.96.

10

15

20

Example 23

The preparation of 4'-[[[2-[(3-methylbutyl)amino]-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid.

25

To 10 mL of dioxane was added 0.159 g of 4'-[[[2-[(3-methylbutyl)amino]-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester and 2 mL of 0.5N aqueous sodium hydroxide. The resulting solution was stirred at room temperature for 72 hours. All solvents were moved and the residue was neutralized with 0.1N hydrochloric acid. The resulting precipitate was collected, washed with water and dried. (0.14 g, 93%) (M.P.=195°-205°C, decomp): ¹H NMR (DMSO-d₆, 300 MHz) δ 8.43 (bs, 1H), 8.03 (m, 1H), 7.70 (m, 1H), 7.59 (m, 1H), 7.45 (m, 5H), 7.21 (m, 3H), 7.01 (m, 1H), 6.50 (bs, 1H), 4.78 (d, 2H), 3.50 (m, 2H), 1.60 (m, 1H), 1.40 (m, 2H), 0.85 (d, 6H); negative FAB MS m/e 439 (M-H). Anal. Calcd for C₂₇H₂₈N₄O₂•1/2 HCl: C, 70.69; H, 6.26; N, 12.53. Found: C, 70.77; H, 6.20; N, 12.53.

30

35

Example 24

The preparation of 4'-[[2,6,7-trimethoxy-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

5

To a solution of 0.141 g 4'-[[2-chloro-6,7-dimethoxy-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester in 20 mL of dry methanol was added 10 mL of hydrogen chloride in dioxane (4 N). The reaction was refluxed for 5 days. All solvents were removed and the residue was purified on silica chroma-
10 tography to yield 0.059 g of the desired product. (42%) (m.p. = 88°-93.5°C): ¹H NMR (DMSO-d₆, 400 MHz) δ 8.56 (t, J=6.1 Hz, 1H), 7.70 (m, 1H), 7.63 (s, 1H), 7.58 (m, 1H), 7.45 (m, 1H), 7.38 (m, 3H), 7.24 (m, 2H), 6.94 (s, 1H), 4.77 (d, J=5.7 Hz, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.81 (s, 3H), 3.58 (s, 3H); positive FAB MS m/e 460 (MH). Anal. Calcd for C₂₆H₂₅N₃O₅•0.865 C₂H₆O: C, 66.70; H, 6.09; N, 8.41. Found: C, 66.56; H, 5.80; N, 8.36.

15

Example 25

The preparation of 4'-[[methyl-[2-(trifluoromethyl)-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid.


20

To a solution of 0.530 g of 4'-[[[2-(trifluoro-methyl)-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid sodium salt in 10 mL of DMF was added 0.181 g of sodium hydride (60% suspension in oil). The reaction mixture was stirred
25 at room temperature for 15 minutes at which time 2.0 mL of methyl iodide was added and stirring was continued for a further 72 hours. All solvents were removed and the residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel chromatography to yield a soft glass (0.420 g). This material was
30 dissolved in 25 mL of dioxane and 10 mL of 1N aqueous sodium hydroxide was added. The reaction solution was stirred at 40°C for approximately 16 hours at which time all the dioxane was removed by evaporation. The desired product crystallized from the remaining water as the sodium salt. The product was recovered by filtration, washed with cold water and dried (0.405 g, 78%). This compound was characterized
35 as its sodium salt: ¹H NMR (DMSO-d₆, 400 MHz) δ 8.22 (d, J=8.5 Hz, 1H), 7.88 (m, 2H), 7.58 (m, 1H), 7.52 (m, 2H), 7.36 (m, 2H), 7.27 (m, 1H), 7.18 (m, 3H), 5.08 (s, 2H), 3.45 (s, 3H); negative FAB MS m/e 459 (M); 436 (M-Na). Anal. Calcd

- 33 -

for $C_{24}H_{17}F_3N_3NaO_2 \cdot 1/4 H_2O$: C, 62.13; H, 3.80; N, 9.06. Found: C, 62.18; H, 3.85; N, 9.03.

- 5 The following examples were or can be prepared using the procedures described in Examples 20-25.



10

Example	R ¹³	R ¹	R ⁸	R ⁷	R ⁵	R ⁴	X
26	H	-CO ₂ Me	H	OMe	OMe	H	HNnBu
27	H	-CO ₂ H	H	H	H	H	NH(CH ₂) ₂ - OMe
28	H	-CO ₂ H	H	OMe	OMe	H	-HNnBu
29	H	-CO ₂ Me	H	OMe	OMe	H	-OH
30	H	CO ₂ H	H	H	H	H	-HNnBu
31	-CH ₂ -	-CO ₂ -	H	H	H	H	CF ₃
	CO ₂ -Me	CH ₂ CO ₂ Me					
32	-CH ₂ -	CO ₂ H	H	H	H	H	CF ₃
	CO ₂ H						

Example 33

The preparation of 4'-[[[2-chlorothieno-[3,2-d]pyrimidin-4-yl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

15

- 34 -

Part A

The preparation of 2,4-thieno[3,2-d]pyrimidinedione.

5 To a solution of 4.6 g of 3-aminothiophene-2-carboxamide in 125 mL of pyridine were added 3.89 g of urea and 10 drops of 6 N hydrochloric acid. The reaction was refluxed overnight and most of the pyridine was removed by evaporation. The residue was suspended in water and adjusted to pH=6 with dilute hydrochloric acid. The solid precipitate was collected by filtration, washed with water and dried to
10 yield the product as an off white powder (3.47 g, 65%); ¹H NMR (DMSO-d₆, 300 MHz) δ 11.58 (s, 1H), 11.20 (s, 1H), 8.05 (d, 1H), 7.95 (d, 1H).

Part B

15 The preparation of 2,4-dichloro thieno[3,2-d]pyrimidine

Phosphorous oxychloride (15 mL) was added to 1.95 g of 2,4-thieno[3,2-d]pyrimidindione. Dimethylaniline (1 mL) was added and the reaction mixture was heated to reflux for 4 1/2 hours. After cooling to room temperature, the reaction
20 mixture was quenched into a 0°C mixture of diethyl ether and water. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated to yield the product. As a brown/yellow solid (1.7 g, 71%).

Part C

25

The preparation of 4'-[[[2-chlorothieno-[3,2-d]pyrimidine-4-yl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester.

Sodium acetate (1.2 g), 2,4-dichlorothieno[3,2-d]pyrimidine(0.75 g) and 4'-aminomethyl(1,1'-biphenyl)-2-carboxylic acid methylester hydrochloride (1.02 g) were
30 suspended in 40 mL of tetrahydrofuran. The reaction mixture was stirred at room temperature for 3 days at which time all the THF was removed by evaporation. The residue was partitioned between ethyl acetate and saturated aqueous sodium carbonate. The organic layer was dried over anhydrous magnesium sulfate, filtered and
35 evaporated. The residue was purified on silica gel chromatography (ETOAc/Hexane) to yield the product as a buff powder (0.81 g, 54%) (m.p.=177°-182°C): ¹H NMR (DMSO-d₆, 400 MHz) δ 8.98 (t, J=6.0 Hz, 1H), 8.19 (d, J=5.4 Hz, 1H), 7.71 (dd,

- 35 -

J=1.1; 7.7 Hz, 1H), 7.60 (m, 1H), 7.46 (m, 1H), 7.38 (m, 4H), 7.25 (m, 2H), 4.73 (d, J=5.9 Hz, 2H), 3.58 (s, 3H); positive FAB MS m/e 410 (MH); 376 (M-Cl+H). Anal. Calcd for C₂₁H₁₆ClN₃O₂S: C, 61.54; H, 3.93; N, 10.25. Found: C, 61.20; H, 4.03; N, 9.89.

5

Example 34

The preparation of 4'-[[[2-chlorothieno-[3,2-d]pyrimidin-4-yl]amino]methyl]-[1,1'-biphenyl]-2-carboxylic acid.

10

To a solution of 0.46 g of 4'-[[[2-chlorothieno-[3,2-d]pyrimidin-4-yl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester in 10 mL of dioxane/methanol (1:1) was added 5 mL of aqueous sodium hydroxide. This solution was stirred at room temperature for 7 days. All solvents were evaporated and the residue was neutralized with hydrochloric acid. The resulting suspension was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica chromatography to yield the desired product. (0.32 g, 73%). This compound was characterized as its sodium salt: ¹H NMR (DMSO-d₆, 400 MHz) δ 9.08 (t, J=5.95 Hz, 1H), 8.18 (d, J=5.4 Hz, 1H), 7.20-7.40 (m, 9H), 4.69 (d, J=5.8 Hz, 2H); negative FAB MS m/e 416 (M-H); 394 (M-Na). Anal. Calcd for C₂₀H₁₃ClN₃NaO₂S•1.25 H₂O: C, 54.55; H, 3.55; N, 9.54. Found: C, 54.37; H, 3.37; N, 9.36.

25

Example 35

The preparation of N-[[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-amine.

30

Part A

The preparation of 2-trifluoromethyl-4-thieno[3,2-d]pyrimidinone.

To 3.80 g of trifluoroacetamide was added 3.19 g of 3-aminothiophene-2-carboxamide. The solids were mixed intimately and heated to 180°C for 2 hours. The reaction was cooled to room temperature and the resulting solid mass was recrystallized

35

- 36 -

from ethanol to yield 1.80 g of the desired product (36%): ^1H NMR (DMSO- d_6 -300 MHz) δ 14.00 (bs, 1H), 8.40 (d, 1H), 7.60 (d, 1H).

Part B

5

The preparation of 4-chloro-2-trifluoromethylthieno[3,2-d]pyrimidine.

To 20 mL of phosphorous oxychloride was added 1.8 g of 2-trifluoromethyl-4-thieno[3,2-d]pyrimidinone. Dimethylaniline (1 mL) was added and the reaction mixture was heated at reflux for 4 hours. The reaction was cooled to room temperature and quenched into a 0°C mixture of diethyl ether and water. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to yield the product as a yellow/brown semi-solid. (1.93 g, 99%).

15

Part C

The preparation of N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-amine.


Sodium acetate (2.6 g), 4-chloro-2-trifluoromethylthieno[3,2-d]pyrimidine (1.33 g), 4'-[[2'-(1H-tetrazol-5-yl) and [1,1'-biphenyl]methyl]amine hydrochloride (1.41 g) were suspended in 50 mL of tetrahydrofuran. The reaction was heated at reflux for 6 days at which time all solvents were removed by evaporation. The residue was eluted from a silica gel column to provide 1.19 g of pure product (47%). This compound was characterized as its potassium salt: ^1H NMR (DMSO- d_6 , 400 MHz) δ 9.05 (m, 1H), 8.27 (d, $J=5.4$ Hz, 1H), 7.54 (m, 2H), 7.35 (m, 3H), 7.21 (m, 2H), 7.08 (m, 2H), 4.72 (d, $J=6$ Hz, 2H); negative FAB MS m/e 490 (M-H); 452 (M-K). Anal. Calcd for $\text{C}_{21}\text{H}_{13}\text{F}_3\text{KN}_7\text{S}\cdot 2.5\text{H}_2\text{O}$: C, 47.00; H, 3.38; N, 18.27. Found: C, 47.00; H, 3.62; N, 17.90.

30

The following examples were or can be prepared using the procedures described in Examples 33-35.

35

- 37 -



Example	R ¹³	R ¹	R ⁵	R ⁴	-	-	X
36	H	CO ₂ Na	H	H	-	-	CF ₃
37	H	5-tetrazolyl	H	H	-	-	Cl

5

Example 38

The preparation of 4'-[[2-(pentafluoromethyl)-4-quinazolinyl]amino][1,1'-biphenyl]-2-carboxylic acid methyl ester.

10

Part A

The preparation of 4'-nitro (1,1'-biphenyl)-2-carboxylic acid methyl ester.

15

To a solution of 2-carboxy-4'-nitro biphenyl (5.29) in 100 mL of anhydrous methanol was added 10 mL of HCl in dioxane (4 N). The reaction was heated at reflux for 16 hrs. The reaction was cooled and all solvents were removed in vacuo. The crude ester (5.65 g) was carried to the next step with no further purification.

20

Part B

The preparation of 4'-amino (1,1'-biphenyl)-2 carboxylic acid methyl ester.

25

The crude ester from part A was dissolved in 100 mL of methanol and 4.0 mL of 12 N hydrochloric acid was added. Palladium on carbon (10%; 0.6 g) was added and the reaction was hydrogenated at ~50 psi for 24 hrs. The reaction was filtered and all solvents were removed in vacuo to yield a tan solid: ¹H NMR (DMSO-d₆, 200 MHz) δ 7.76(m, 1H), 7.60(m, 1H), 7.49(m, 1H), 7.38(m, 5H), 3.60(s, 3H).

- 38 -

Part C

The preparation of 4'-[[2-(pentafluoromethyl)-4-quinazolinyl]amino][1,1'-biphenyl]-2-carboxylic acid methyl ester.

5

Sodium acetate (4.8 g), 4-chloro-2-(pentafluoroethyl)quinazoline (1.53 g) and 1.57 g of 4'-amino (1,1'-biphenyl)-2-carboxylic acid methyl ester were stirred at 45°C in 100 mL of tetrahydrofuran. After 72 hours all solvents were evaporated and the residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated. The resulting solid was recrystallized from ethyl acetate/hexane to give 1.65 g of the desired product (64%) (M.P.=206.5°-208°C): ¹H NMR (DMSO-d₆, 400 MHz) δ 10.37 (s, 1H), 8.72 (d, J=8.4Hz, 1H), 7.97 (m, 1H), 7.83 (m, 1H), 7.72 (m, 1H), 7.62 (m, 1H), 7.48 (m, 2H), 7.35 (d, J=8.6Hz, 2H), 3.61 (s, 3H); positive FAB MS m/e 474(MH). Anal. calcd for C₂₄H₁₆F₅N₃O₂: C, 60.89; H, 3.41; N, 8.88. Found: C, 61.01; H, 3.76; N, 8.86.

10

15

Example 39

20 The preparation of 4'-[[2-(pentafluoromethyl)-4-quinazolinyl]amino][1,1'-biphenyl]-2-carboxylic acid.

25


30

35

To a solution of 1.0 g of 4'-[[2-(pentafluoro ethyl)-4-quinazolinyl]amino][1,1'-biphenyl]-2-carboxylic acid methyl ester in 20 mL of dioxane was added 20 mL of aqueous sodium hydroxide. The mixture was stirred at 75°C for 18 hours at which time all solvents were removed. The residue was partitioned between ethyl acetate and 2 N hydrochloric acid. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated. The residue was purified on silica gel (ethyl acetate/hexane) to yield 0.780 g of the desired product (80%). This compound was characterized as its sodium salt: ¹H NMR (DMSO-d₆, 400 MHz) δ 11.58 (bs, 1H), 8.97 (d, J=8.4Hz, 1H), 7.98 (d, J=8.4Hz, 2H), 7.91 (m, 2H), 7.60 (m, 1H), 7.48 (m, 2H), 7.41 (m, 1H), 7.26 (m, 3H); negative FAB MS m/e 480(M-H); 458(M-Na). Anal. calcd for C₂₃H₁₃F₅N₃NaO₂ 2H₂O: C, 53.39; H, 3.31; N, 8.12. Found: C, 53.33; H, 3.47; N, 8.43.

- 39 -

The following example was or can be prepared using the procedures described in examples 38 and 39.



5


Example	R ¹³	R ¹	R ⁸	R ⁷	R ⁵	R ⁴	X
40	H	CO ₂ Na	H	H	H	H	CF ₃

- 40 -

CLAIMS

We claim:

1. A compound of formula I:



I

- 10 wherein A is O, S, NR⁶, -CR⁷=CR⁸-;
 Z is O, S, NR⁶, -CR⁷=CR⁸-;
 X is H, NR⁹R¹⁰, OR¹¹, CN, F, Cl, I, Br, perfluoroalkyl,
 alkyl,
 alkyl-OH, alkoxyalkyl, -(CH₂)_nCO₂R¹¹,
 15 -(CH₂)_nCONR⁹R¹⁰;
 with the proviso that when Z = -CR⁷=CR⁸- then Y is NR¹³,
 NR¹³CR¹²R¹⁴, CR¹²R¹⁴NR¹³;
 with the proviso that when Z = O, S, NR⁶ then Y is
 NR¹³CR¹²R¹⁴;
 20 R¹ is 5-tetrazolyl, CO₂R¹¹, SO₃H, NHSO₂CH₃, NHSO₂CF₃;
 R², R³, R⁴, R⁷, R⁸ is H, alkyl, alkoxyalkyl, alkyl-OH,
 perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³,
 -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰, OR¹¹, F, Cl, Br, I,
 NR⁹R¹⁰;
 25 with the proviso that when A = -CR⁷=CR⁸- then R⁵ is alkyl,
 alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H,
 -CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰,
 -OH, OR¹¹, F, Cl, Br, I, NR⁹R¹⁰;
 with the proviso that when A = O, S, NR⁶ then R⁵ is alkyl,
 30 alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H,

- 41 -

-CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹,
 -(CH₂)_nCONR⁹R¹⁰;

R⁶ is H, alkyl, aralkyl;

R⁹, R¹⁰ is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl,
 aralkyl;

R¹¹ is H, alkyl, aralkyl, alkoxyalkyl;

R¹², R¹⁴ is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH,
 perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³,
 -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰;

R¹³ is H, OR¹¹, alkyl, perfluoroalkyl, aralkyl,
 -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰;

n is 0, 1, 2 or 3 or a N-oxide thereof

or a pharmaceutically acceptable salt, solvate or hydrate of the compound of formula (I)
 or the N-oxide.

2. A compound of claim 1 wherein:

A is S, -CR⁷=CR⁸-;

Z is S, -CR⁷=CR⁸-;

X is H, CN, F, Cl, perfluoroalkyl, alkyl,
 alkyl-OH, alkoxyalkyl, -(CH₂)_nCO₂R¹¹,
 -(CH₂)_nCONR⁹R¹⁰;

with the proviso that when Z= -CR⁷=CR⁸- then Y is -NR¹³,
 -NR¹³CR¹²R¹⁴;

with the proviso that when Z= S, then Y is NR¹³CR¹²R¹⁴;

R¹ is 5-tetrazolyl, CO₂H, SO₃H, NHSO₂CF₃;

R², R³, R⁴, R⁷, R⁸= H, alkyl, alkoxyalkyl, alkyl-OH,
 perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³,
 -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰, OR¹¹, F, Cl, Br, I,
 NR⁹R¹⁰;

with the proviso that when A= -CR⁷=CR⁸- then R⁵ is alkyl,
 alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H,
 -CN, NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹,
 -(CH₂)_nCONR⁹R¹⁰, -OH, OR¹¹, F, Cl, Br, I, NR⁹R¹⁰;

- 42 -

with the proviso that when A= S then R⁵ is alkyl, alkoxy,
 alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN,
 NO₂, SO₂R¹³, -(CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰;
 R⁹, R¹⁰ is H, alkyl, perfluoroalkyl, aralkyl;
 5 R¹¹ is H, alkyl, aralkyl, alkoxyalkyl;
 R¹², R¹⁴ is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH,
 perfluoroalkyl, aralkyl, CN, NO₂;
 R¹³ is H, OR¹¹, alkyl, perfluoroalkyl, aralkyl,
 (CH₂)_nCO₂R¹¹, -(CH₂)_nCONR⁹R¹⁰;
 10 n is 0, 1, 2 or 3
 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

3. A compound of claim 2 wherein:

15 A is -CR⁷=CR⁸-, S;
 Z is -CR⁷=CR⁸-, S
 X is H, Cl, perfluoroalkyl, alkyl;
 with the proviso that when Z= -CR⁷=CR⁸- then Y is -NR¹³,
 -NR¹³CR¹²R¹⁴;
 20 with the proviso that when Z= S, then Y is NR¹³CR¹²R¹⁴;
 R¹ is 5-tetrazolyl, CO₂H SO₃H, NHSO₂CF₃;
 R², R³, R⁴, R⁷, R⁸ is H, alkyl, alkoxyalkyl, alkyl-OH,
 perfluoroalkyl, aralkyl, CN, NO₂, SO₂R¹³, OR¹¹, F, Cl,
 Br, I, NR⁹R¹⁰;
 25 with the proviso that when A= -CR⁷=CR⁸- then R⁵ is alkyl,
 alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H,
 -CN, NO₂, SO₂R¹³, -OH, OR¹¹, F, Cl, Br, I, NR⁹R¹⁰;
 with the proviso that when A= S then R⁵ is alkyl, alkoxy,
 alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, -CN,
 30 NO₂, SO₂R¹³;
 R⁹, R¹⁰ is H, alkyl, perfluoroalkyl, aralkyl;
 R¹¹ is H, alkyl, aralkyl, alkoxyalkyl;
 R¹², R¹⁴ is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH,
 perfluoroalkyl, aralkyl;
 35 R¹³ is H, OR¹¹, alkyl, perfluoroalkyl, aralkyl;
 n is 0, 1, 2 or 3

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

4. A compound of claim 1 which is 4'-[[2-chloro-4-quinazolinyl]amino]methyl]-[1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 5 5. A compound of claim 1 which is 4'-[[2-chloro-6,7-dimethoxy-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
6. A compound of claim 1 which is 4'-[[2-(butylamino)-6,7-dimethoxy-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a
10 pharmaceutically acceptable salt, solvate or hydrate thereof.
7. A compound of claim 1 which is 4'-[[2-(3-methylbutyl)amino]-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
8. A compound of claim 1 which is 4'-[[2-chloro-4-quinazolinyl]amino]methyl]-
15 [1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
9. A compound of claim 1 which is 4'-[[2-hydroxy-6,7-dimethoxy-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 20 10. A compound of claim 1 which is 4'-[[2,6,7-trimethoxy-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt, solvate or hydrate thereof.
11. A compound of claim 1 which is 4'-[[2-hydroxy-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable
25 salt, solvate or hydrate thereof.
12. A compound of claim 1 which is 4'-[[2,6-dichloro-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 44 -


13. A compound of claim 1 which is 4'-[[2-(hydroxy-4-quinazolinyl)amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
14. A compound of claim 1 which is 4'-[(4-quinazolinylamino)methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
15. A compound of claim 1 which is 4'-[[2-(butylamino)-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
16. A compound of claim 1 which is 4'-[[2-(acetyloxy)-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt, solvate or hydrate thereof.
17. A compound of claim 1 which is 4'-[[2-(trifluoromethyl)-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt, solvate or hydrate thereof.
18. A compound of claim 1 which is 4'-[[2-(trifluoromethyl)-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
19. A compound of claim 1 which is N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
20. A compound of claim 1 which is 2-chloro-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-quinazolinamine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
21. A compound of claim 1 which is '[[[7-chloro-2-(trifluoromethyl)-4-quinazolinyl]-amino]methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
22. A compound of claim 1 which is 4'-[[2-(pentafluoroethyl)-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.

23. A compound of claim 1 which is 4'-[[[2,7-bis(trifluoromethyl)-4-quinazolinyl]-amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
24. A compound of claim 1 which is 4'-[[[2-(trifluoromethyl)-4-quinazolinyl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
25. A compound of claim 1 which is 6-methyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
26. A compound of claim 1 which is 8-methyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
27. A compound of claim 1 which is 5-methyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)-4-quinazolinamine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
28. A compound of claim 1 which is 4'-[[[2-(trifluoromethyl)-4-quinazolinyl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
29. A compound of claim 1 which is 4'-[[methyl-[2-(trifluoromethyl)-4-quinazolinyl]-amino]methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
30. A compound of claim 1 which is 2-methyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-4-quinazolinamine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
31. A compound of claim 1 which is 4'-[[2-chlorothieno[3,2-d]pyrimidin-4-yl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt, solvate or hydrate thereof.
32. A compound of claim 1 which is 4'-[[2-chlorothieno[3,2-d]pyrimidin-4-yl]amino]-methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.


- 46 -

33. A compound of claim 1 which is N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-2-(trifluoromethyl)thieno[3,2-d]pyrimidin-4-amine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
34. A compound of claim 1 which is 4'-[[[2-(trifluoromethyl)thieno[3,2-d]-pyrimidin-4-yl]amino]methyl][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
35. A compound of claim 1 which is 2-chloro-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]thieno[3,2-d]pyrimidin-4-amine or a pharmaceutically acceptable salt, solvate or hydrate thereof.
36. A compound of claim 1 which is 2-[5-[[[2-(trifluoromethyl)-4-quinazoliny]-amino]-methyl]-2-thienyl]benzoic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
37. A compound of claim 1 which is 4'-[[2-(trifluoromethyl)-4-quinazoliny]-amino][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
38. A compound of claim 1 which is 4'-[[2-(pentafluoroethyl)-4-quinazoliny]-amino][1,1'-biphenyl]-2-carboxylic acid or a pharmaceutically acceptable salt, solvate or hydrate thereof.
39. A pharmaceutical composition containing a compound of claim 1, in an amount effective for producing a hypotensive response in a mammal, and a pharmaceutically acceptable carrier, vehicle or diluent.
40. A method for producing hypotensive activity in a mammal by administering to that mammal a compound of claim 1 in a hypotensively effective amount.
41. A method for preventing or treating restenosis following angioplasty in a mammal by administering to that mammal a compound of formula I.
42. A process for preparing a compound claimed in Claim 1 which comprises
- (a) condensing, eg in the presence of a base, a compound of formula

- 47 -



with a compound of formula



wherein the above formulae R, R², R³, R⁴, R⁵, X and Z are as defined in Claim 1 and


- 5 (i) Z¹ is a leaving group and Y¹ is NHR¹³ or NHR¹³CR¹²R¹⁴ (where R¹², R¹³ and R¹⁴ are as defined in Claim 1)

or


- (ii) Z¹ is -NHR¹³ or -CR¹²R¹⁴NHR¹³ and Y¹ is a leaving group (where R¹², R¹³ and R¹⁴ are as defined in Claim 1)

10 or

- (b) reacting a compound of formula



where R⁴, R⁵, A, X, Y and Z are as defined in Claim 1 and Z² is chloro or bromo with an aryl species of formula



Q = B(OH)₂ or MgX¹ or ZnX¹
(where X¹ is halogen)


15

in the presence or absence of a catalytic compound containing palladium or nickel where R¹ and R² are as defined in Claim 1

or

- (c) converting an oxazoline of formula

- 48 -



(where R^3 , R^4 , R^5 , A , X , Y and Z are as defined in Claim 1) into a compound of formula I in which R^2 is hydrogen and R^1 is 5-tetrazolyl or $-CO_2R^{11}$ (where R^{11} is defined in Claim 1) by methods known per se

5 or

(d) converting one compound of formula (I) into another compound of formula (I) by methods known per se

or

(e) forming a salt of the compound of formula (I) with an inorganic or organic base

10 or

(f) converting a compound of formula (I) or a salt thereof to an N-oxide by means of a peroxidising agent.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl. 5	C 07 D 239/94	C 07 D 403/12
C 07 D 495/04	C 07 D 405/12	C 07 D 491/04
A 61 K 31/505		C 07 D 487/04
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int. Cl. 5	C 07 D 239/00	C 07 D 403/00
	C 07 D 495/00	C 07 D 405/00
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP, A, 0443568 (TAKEDA) 28 August 1991, see page 35, table 10A; pages 36-45 -----	1, 39, 42
<p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
10-02-1993	- 4. 03. 93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	FRANÇOIS, J.	

INTERNATIONAL SEARCH REPORT

International application no.

PCT/US 92/08991

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 40, 41 are directed to a method of treatment of animal body, the search has been carried out and based on the attributed effects of the compounds."
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9208991

SA 67403

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 26/02/93
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0443568	28-08-91	None	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINE(S) OR MARK(S) ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.